CELEX: 62013CA0691
Language: en
Date: 2015-02-26 00:00:00
Title: Case C-691/13: Judgment of the Court (Third Chamber) of 26 February 2015 (request for a preliminary ruling from the Conseil d'État — France) — Les Laboratoires Servier SA v Ministre des Affaires sociales et de la Santé, Ministre de l’Économie et des Finances (Reference for a preliminary ruling — Medicinal products for human use — Directive 89/105/EEC — Article 6(2) — Establishment of a list of medicinal products reimbursed by the health insurance funds — Amendment of the conditions of reimbursement of a medicinal product when renewing its inclusion in such a list — Obligation to state reasons)

27.4.2015   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 138/17
            
         Judgment of the Court (Third Chamber) of 26 February 2015 (request for a preliminary ruling from the Conseil d'État — France) — Les Laboratoires Servier SA v Ministre des Affaires sociales et de la Santé, Ministre de l’Économie et des Finances
   (Case C-691/13) (1)
   
   ((Reference for a preliminary ruling - Medicinal products for human use - Directive 89/105/EEC - Article 6(2) - Establishment of a list of medicinal products reimbursed by the health insurance funds - Amendment of the conditions of reimbursement of a medicinal product when renewing its inclusion in such a list - Obligation to state reasons))
   (2015/C 138/22)
   Language of the case: French
   
      Referring court
   
   Conseil d'État
   
      Parties to the main proceedings
   
   
      Applicant: Les Laboratoires Servier SA
   
      Defendant: Ministre des Affaires sociales et de la Santé, Ministre de l’Économie et des Finances
   
      Operative part of the judgment
   
   Article 6(2) of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems must be interpreted as meaning that the obligation to state reasons set out in that provision is applicable to a decision which reinstates a product in the list of medicinal products covered by the health insurance system, but which limits the reimbursement of that product to a specific category of patients.
   
      (1)  OJ C 85, 22.3.2014.